RECURSION PHARMACEUTICALS, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $19.45 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-28.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2025-02-28
- RECURSION PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-09-30 was $5.72M, a 3385.98% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-06-30 was $10.47M, a 1536.25% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-03-31 was $3.27M, a 7.22% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $19.45M, a 291.61% increase from fiscal 2023.
- RECURSION PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $4.97M, a 25.77% increase from fiscal 2022.
- RECURSION PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $3.95M.
- RECURSION PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $0.00.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $5.72M derived: sum of 2 quarters · filed 2025-02-28 | $16.19M derived: sum of 3 quarters · filed 2025-02-28 | $19.45M 10-K · filed 2025-02-28 |
| 2024-09-30 | $5.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $16.19M derived: sum of 2 quarters · filed 2024-11-06 | $19.45M 10-Q · filed 2024-11-06 | $20.10M derived: sum of 4 quarters · filed 2025-02-28 |
| 2024-06-30 | $10.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $13.74M 10-Q · filed 2024-08-08 | $14.38M derived: sum of 3 quarters · filed 2025-02-28 | $14.55M derived: sum of 4 quarters · filed 2025-02-28 |
| 2024-03-31 | $3.27M 10-Q · filed 2024-05-09 | $3.91M derived: sum of 2 quarters · filed 2025-02-28 | $4.07M derived: sum of 3 quarters · filed 2025-02-28 | $4.71M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-12-31 | $644.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $808.00K derived: sum of 2 quarters · filed 2025-02-28 | $1.45M derived: sum of 3 quarters · filed 2025-02-28 | $4.97M 10-K · filed 2025-02-28 |
| 2023-09-30 | $164.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $804.00K derived: sum of 2 quarters · filed 2024-11-06 | $4.32M 10-Q · filed 2024-11-06 | $4.32M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $640.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $4.16M 10-Q · filed 2024-08-08 | $4.16M derived: sum of 3 quarters · filed 2025-02-28 | $4.12M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $3.52M 10-Q · filed 2024-05-09 | $3.52M derived: sum of 2 quarters · filed 2025-02-28 | $3.48M derived: sum of 3 quarters · filed 2025-02-28 | $5.92M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$40.00K derived: sum of 2 quarters · filed 2025-02-28 | $2.40M derived: sum of 3 quarters · filed 2025-02-28 | $3.95M 10-K · filed 2025-02-28 |
| 2022-09-30 | -$40.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $2.40M derived: sum of 2 quarters · filed 2023-11-09 | $3.95M 10-Q · filed 2023-11-09 | $3.95M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $2.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $3.99M 10-Q · filed 2023-08-08 | $3.99M derived: sum of 3 quarters · filed 2024-02-29 | $3.99M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $1.55M 10-Q · filed 2023-05-08 | $1.55M derived: sum of 2 quarters · filed 2024-02-29 | $1.55M derived: sum of 3 quarters · filed 2024-02-29 | $1.55M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $0.00 derived: sum of 2 quarters · filed 2024-02-29 | $0.00 derived: sum of 3 quarters · filed 2024-02-29 | $0.00 10-K · filed 2024-02-29 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $0.00 derived: sum of 2 quarters · filed 2022-11-08 | $0.00 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $0.00 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |